1stOncology™: Cancer Intelligence Service – Page 8838 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme

On July 8, 2021 Vect-Horus and RadioMedix reported the FDA clearance of exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the detection and mapping of Low Density Lipoprotein Receptor (LDLR) overexpressed in Glioblastoma Multiforme (GBM) (Press release, Vect-Horus, JUL 8, 2021, View Source [SID1234584710]). The Phase 1 exploratory study sponsored by RadioMedix will start enrollment upon IRB « Internal Review Board » approval. The study will investigate safety, dosimetry and distribution of 68Ga-RMX-VH in patients with primary or recurrent GBM. The eIND clinical study will proceed in Excel Diagnostic and Nuclear Oncology Center (Houston, TX).
Glioblastoma multiforme is one of the most aggressive brain tumors in humans and is a serious and life-threatening condition. RMX-VH conjugate targets the LDLR, which is overexpressed in many cancer cells, including glioblastoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Vect-Horus and RadioMedix signed in October 2019 a partnership agreement to co- develop radiotheranostic agent for the diagnosis (Dx) and radiotherapy (Rx) of GBM using Vect-Horus expertise in targeting tumors and RadioMedix know-how in developing radiopharmaceuticals. Under the terms of the collaboration, both parties will share the costs of development until Phase 1 (Dx & Rx). The radiotheranostic agent will be then out licensed to RadioMedix for further clinical development and commercialization.

"We look forward to embarking on our next chapter as a clinical-stage company, harnessing the power of our platform VECTrans to discover and develop new vectors that can target different tissues" said Alexandre Tokay, CEO of Vect-Horus.
"The FDA clearance marks a significant step in the continuing development of 68Ga-RMX-VH as well as our collaboration with RadioMedix. We are excited to follow the progress of this agent and the upcoming clinical trial" said Dr Jamal Temsamani, Director of Drug Development of Vect-Horus.

"GBM is one of the most aggressive human cancers and new diagnostic probes and targeted therapies are desperately needed to address this unmet need. The pre-clinical studies on RMX-VH ligand is highly promising and we are hoping to see similar targeting effectiveness in human GBM" said Dr Ebrahim Delpassand, CEO of RadioMedix.

"We are excited to initiate first in human exploratory clinical study of 68Ga-RMX-VH and evaluate the LDLR-targeting properties of this agent in GBM" said Izabela Tworowska, PhD, CSO of RadioMedix. "Our long-term-goal is to develop radiotheranostic drug for glioblastoma multiforme and expend the treatment option available for GBM patients."

Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021

On July 8, 20221 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in one-on-one investor meetings and Chief Science Officer, Takashi Kei Kishimoto, Ph.D., will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 to be held virtually, July 14-15 (Press release, Selecta Biosciences, JUL 8, 2021, View Source [SID1234584709]).

Details on the panel can be found below.

Title: Delivery and Durability of Genetic Medicines
Date & Time: Thursday, July 15 at 10:00 a.m. ET

OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference

On July 8, 2021 OPKO Health, Inc. (NASDAQ: OPK) reported that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021 (Press release, Opko Health, JUL 8, 2021, View Source [SID1234584702]). Management will be interviewed in a fireside chat format on Tuesday, July 13th at 8:30 a.m. Eastern time and will also be holding one-on-one virtual meetings with investors throughout the day.

The fireside chat will be archived in the Investors section of OPKO Health’s website and will be available here.

Miravo Healthcare™ to Present at Access to Giving Virtual Investor Conference

On July 8, 2021 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, reported that it has been invited to present at the Access to Giving Virtual Investor Conference, which is being held virtually on July 13th – 15th, 2021 (Press release, Nuvo Pharmaceuticals, JUL 8, 2021, View Source [SID1234584701]). Jesse Ledger, Miravo’s President & Chief Executive Officer and Mary-Jane Burkett, Miravo’s Vice President & Chief Financial Officer will be presenting at the conference.

Access to Giving is a conference themed around investor education and advocacy with 50+ companies presenting, a keynote, three distinctive panels and management will be available for 1×1 meetings.

DATE: Thursday, July 15, 2021

TIME: 9:30 a.m. ET

LIVE PRESENTATION /
REPLAY LINK: View Source

To receive additional information, request an invitation or to schedule a 1×1 meeting, please email [email protected]. Investors can register here.

About Access to Giving

Access to Giving is the first-of-its-kind virtual investor conference and will be held July 13th – 15th, 2021. Companies will have the opportunity to tell their story and conduct 1×1 meetings with qualified investors for charity. 100% of monies raised through donations for 1×1 meetings will be given to causes that are focused on financial literacy and financial education.

Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference

On July 8, 2021 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a neuropsychology-focused panel discussion at the William Blair Biotech Focus Conference at 12:00 p.m. Eastern Time on Thursday July 15, 2021 (Press release, Neurocrine Biosciences, JUL 8, 2021, View Source [SID1234584700]).

The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.